Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of TAK-881 in Healthy Adults
NCT05059977Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- SC (Subcutaneous administration)
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-881 in primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site at Day 4. Started Oct 2021; status: completed.
02
Drugs
TAK-881
03
Conditions
primary immunodeficiency (PI)chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05059977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059977.